DOCSLIB.ORG

Proteasome Network in Prostate Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proteasome Network in Prostate Carcinoma Prostate Cancer and Prostatic Diseases (2011) 14, 38–45 & 2011 Macmillan Publishers Limited All rights reserved 1365-7852/11 www.nature.com/pcan ORIGINAL ARTICLE Transcription alterations of members of the ubiquitin–proteasome network in prostate carcinoma OJC Hellwinkel1,2,5, LE Asong3,5, J-P Rogmann3,HSu¨ ltmann4, C Wagner2, T Schlomm2 and C Eichelberg3 1Department of Legal Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 2Martini-Klinik, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 3Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany and 4Working Group Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany The purpose of this work was to investigate the role of the ubiquitin–proteasome network (UPN) in prostate cancer (PCA) and to elicit potential markers for this disease. The UPN represents a key factor in the maintenance of cellular homoeostasis as a result of its fundamental function in the regulation of intracellular protein degradation. Members of this network have a role in the biology of haematological and solid tumours. Tumour cells and normal epithelial cells from 22 prostatectomy specimens were isolated by laser microdissection. Prostate biopsy samples from healthy individuals served for technical calibration and as controls. Transcript levels of eight selected genes with E3 ubiquitin ligase activity (labelling target proteins for proteasome degradation) and two genes belonging to the proteasome–multienzyme complex itself were analysed by quantitative real-time RT-PCR. The proteasome genes PSMC4 and PSMB5 and the E3 ubiquitin ligase NEDD4L were significantly and coherently upregulated in PCA cells compared with the corresponding adjacent normal prostate tissue. Transcription of the E3 ubiquitin ligase SMURF2 was significantly higher in organ-confined tumours (pT2) compared with non-organ- confined cancers (pT3). The results indicate a role for PSMC4 and PSMB5 and the E3 ubiquitin ligase NEDD4L in prostate tumourigenesis, whereas SMURF2 downregulation could be associated with clinical progression. NEDD4L and SMURF2 both target transforming growth factor (TGF)-b for degradation. This reflects the pleiotropic role of the TGF-b signalling pathway acting as a tumour suppressor in normal and pre-cancerous cells, but having oncogenic properties in progressing cancer. Further studies have to elucidate whether these alterations could represent clinically relevant PCA-diagnostic and progression markers. Prostate Cancer and Prostatic Diseases (2011) 14, 38–45; doi:10.1038/pcan.2010.48; published online 23 November 2010 Keywords: proteasome; E3 ubiquitin ligase; transcription; prostate carcinoma; tumour marker Introduction cycle progression, signal transduction, proliferation, apoptosis, modulation of surface receptors and regula- Knowledge about expression patterns of genes involved tion of tumour suppression proteins2–4 (Figure 1). Pro- in the control of cellular homoeostasis is important to teins for proteasome degradation are labelled by understand malign transformation and cancer progres- conjugation of multiple ubiquitin moieties (ubiquitina- sion, and could improve cancer diagnosis and staging. tion). Ubiquitin is an abundant small highly conserved, Cellular disposal of molecules is essential for normal composed of 76 amino acids, protein found only in cellular homoeostasis. The ubiquitin–proteasome net- eukaryotes, and is transferred by a cascade of three work (UPN) is accountable for the selective cellular enzyme types: protein E1 activates the C-terminus of the removal of mis-folded, damaged, and unassembled ubiquitin, whereas E2 transfers the activated ubiquitin to polypeptide chains and regulatory proteins.1–2 It reg- one of the multiple E3 ubiquitin ligase proteins. E3 ulates numerous basic cellular processes such as cell ubiquitin ligases are responsible for the specificity of protein recognition and ubiquitination, thus ensuring the fidelity of selective proteolysis. The proteasome is a Correspondence: Dr OJC Hellwinkel, Department of Legal Medicine, 2.2 MDa barrel-shaped multi-catalytic proteinase com- Transplantation Tissue Bank (Building W40, 2nd floor), University plex, the 26S proteasome, composed of two complexes, a Hospital Eppendorf, Martinistrasse 52, Hamburg 20246, Germany. 20S core particle and a 19S regulator cap. The 20S core E-mail: [email protected] 5These authors contributed equally to this work. contains the protease subunits and is composed of four Received 22 July 2010; revised 27 September 2010; accepted 17 rings (two identical peripheral alpha rings and two October 2010; published online 23 November 2010 identical central beta rings), each ring containing seven Transcription alterations in prostate carcinoma OJC Hellwinkel et al 39 p53 TH1 Mcm7 7 3 2 SMAD1 Degradation products TGF UBE3A * 1R SMURF2 * SMAD2 NEDD4L * p53 Poly- Ubiquitin PSMC4 * PSMB5 * label IGF-IR MDM2 * Ub Ub Ub PTEN NEDD4 * 19S 20S 19S IGF-IR regulator core regulator proteasome HECW1 * DVL1 SIAH1 * SOD1 CBL * DCC -Cat EDF-R PDGF IGF-IR -R Figure 1 The ubiquitin–proteasome network. The proteasome alongside some E3 ubiquitin ligases (light blue ellipses) are demonstrated. Asterisks illustrate the investigated transcripts. Some tumour-relevant degradation targets are depicted as small green circles. The color reproduction of this figure is available on the html full text version of the manuscript. non-identical subunits (resulting in 2 Â 14 non-identical board was obtained according to the directions of the subunits). The 19S cap (alternative name PA700) is made German authorities. of two sub-complexes, the lid and the base and a total of A total of 22 PCA patients undergoing radical 17 peptide molecules. It contains 11 non-ATPase subunits prostatectomy were included in this study (Table 2; the and 6 ATPases that unfold the substrates and translocate identical collective has been investigated in an earlier them into the core for proteolysis (substrate specificity; for study (see Hellwinkel et al.20097). None of the patients further information see http://www.atlasgeneticsoncology. had been treated with radio-, chemotherapy or ablative org/Deep/UbiquitininCancerID20083.html). The protea- hormonal therapy. Tumour and normal tissue samples some is not only found attached to the endoplasmatic were taken with a 6-mm punch biopsy instrument from reticulum and to the nucleus but is also found free in the tumourous and non-tumourous areas as described cytosol.1–2 Alterations of this critical degradation machin- before.8 The specimens were incubated in RNAlater ery have an important role in tumourigenesis and cancer (Qiagen, Hilden, Germany) at 4 1C for 2 h and then stored progression.4–6 Its hierarchical character further provides a for a long term at –80 1C. To select epithelial (tumour and platform for a novel approach in innovative anti-cancer adjacent normal) cells for gene expression analyses, therapy.5 we performed laser microdissection as previously des- The aim of this pilot study is a compact analysis cribed.7–8 of the transcription patterns of selected important First, the specimens were briefly thawed on ice and ‘representatives’ of those arms of the UPN that control then cryosections of up to 15 mm thickness were prepared (prostate) cancer-relevant pathways (eight E3 ubiquitin and transferred to RNAse-free membrane slides (PALM ligases and two integral members of the proteasome, Microlaser Technologies AG, Bernried, Germany). The Table 1 and Figure 1). Such findings could provide cryosections were air-dried and stained with cresyl violet valuable information on prostate cancer (PCA) biology following standard procedures. Additionally, represen- and further indicate potential diagnostic and prognostic tative sections were hematoxylin and eosin stained for markers. pathological examination and archival storing. To produce samples of highest uniformity, tissue areas containing either only tumour (always both Gleason Materials and methods components at proportions corresponding to the histo- pathological data given in Table 2) or normal prostate Tissue samples, cryosection and laser microdissection duct cells (1000–3000 mm2) were microdissected and Informed consent from the patients involved in this collected employing an ultraviolet laser-based microdis- project and the healthy volunteers (calibrator, see below), section system (PALM Microlaser Technologies) accord- as well as the approval from the institutional review ing to manufacturer’s protocols. Microdissected samples Prostate Cancer and Prostatic Diseases Prostate Cancer and Prostatic Diseases 40 Table 1 Information on the analysed transcripts (catalogue numbers of the used TaqMan real-time RT-PCR assays from Applied Biosystems are given between brackets) Gene symbol Name Aliases Chromosome Function/role in cancer (TaqMan assay) location UBE3A Ubiquitin protein ligase E6-AP; Human papilloma 15q11–q13 E3 ubiquitin-protein ligase. Targets p53, Blk, TH1and itself for (Hs00963673_ml) E3A virus E6-associated protein; degradation. Mediates Mcm7, HHR23A ubiquitination. Overexpressed in FLJ26981 breast cancer compared with adjacent normal tissue. Downregulated in invasive breast and prostate carcinomas compared with adjacent normal tissue. Transcription alterations in prostate carcinoma SMURF2 SMAD-specific E3 E3 ubiquitin-ligase SMURF2; 17q22-q23 E3 ubiquitin-protein ligase. Targets Smad1, Smad2, Smad3, Smad7 and (Hs00909283_ml)
Load more

Recommended publications
  • PSMB5 Antibody Cat
    PSMB5 Antibody Cat. No.: 57-791 PSMB5 Antibody Western blot analysis of PSMB5 using rabbit polyclonal PSMB5 Antibody immunohistochemistry analysis in PSMB5 Antibody using 293 cell lysates (2 ug/lane) either formalin fixed and paraffin embedded human skin tissue nontransfected (Lane 1) or transiently transfected (Lane 2) followed by peroxidase conjugation of the secondary with the PSMB5 gene. antibody and DAB staining. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human This PSMB5 antibody is generated from rabbits immunized with a KLH conjugated IMMUNOGEN: synthetic peptide between 235-263 amino acids from the C-terminal region of human PSMB5. TESTED APPLICATIONS: IHC-P, WB For WB starting dilution is: 1:1000 APPLICATIONS: For IHC-P starting dilution is: 1:10~50 October 1, 2021 1 https://www.prosci-inc.com/psmb5-antibody-57-791.html PREDICTED MOLECULAR 28 kDa WEIGHT: Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: PSMB5 Proteasome subunit beta type-5, Macropain epsilon chain, Multicatalytic endopeptidase ALTERNATE NAMES: complex epsilon chain, Proteasome chain 6, Proteasome epsilon chain, Proteasome subunit MB1, Proteasome subunit X, PSMB5, LMPX, MB1, X ACCESSION NO.: P28074 PROTEIN GI NO.: 187608890 GENE ID: 5693 USER NOTE: Optimal dilutions for each application to be determined by the researcher.
    [Show full text]
  • Role of Phytochemicals in Colon Cancer Prevention: a Nutrigenomics Approach
    Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Marjan J van Erk Promotor: Prof. Dr. P.J. van Bladeren Hoogleraar in de Toxicokinetiek en Biotransformatie Wageningen Universiteit Co-promotoren: Dr. Ir. J.M.M.J.G. Aarts Universitair Docent, Sectie Toxicologie Wageningen Universiteit Dr. Ir. B. van Ommen Senior Research Fellow Nutritional Systems Biology TNO Voeding, Zeist Promotiecommissie: Prof. Dr. P. Dolara University of Florence, Italy Prof. Dr. J.A.M. Leunissen Wageningen Universiteit Prof. Dr. J.C. Mathers University of Newcastle, United Kingdom Prof. Dr. M. Müller Wageningen Universiteit Dit onderzoek is uitgevoerd binnen de onderzoekschool VLAG Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Marjan Jolanda van Erk Proefschrift ter verkrijging van graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof.Dr.Ir. L. Speelman, in het openbaar te verdedigen op vrijdag 1 oktober 2004 des namiddags te vier uur in de Aula Title Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Author Marjan Jolanda van Erk Thesis Wageningen University, Wageningen, the Netherlands (2004) with abstract, with references, with summary in Dutch ISBN 90-8504-085-X ABSTRACT Role of phytochemicals in colon cancer prevention: a nutrigenomics approach Specific food compounds, especially from fruits and vegetables, may protect against development of colon cancer. In this thesis effects and mechanisms of various phytochemicals in relation to colon cancer prevention were studied through application of large-scale gene expression profiling. Expression measurement of thousands of genes can yield a more complete and in-depth insight into the mode of action of the compounds.
    [Show full text]
  • The Role of Protein Clearance Mechanisms in Organismal Ageing and Age-Related Diseases
    REVIEW Received 18 Mar 2014 | Accepted 24 Oct 2014 | Published 8 Dec 2014 DOI: 10.1038/ncomms6659 The role of protein clearance mechanisms in organismal ageing and age-related diseases David Vilchez1, Isabel Saez1 & Andrew Dillin2,3 The ability to maintain a functional proteome, or proteostasis, declines during the ageing process. Damaged and misfolded proteins accumulate with age, impairing cell function and tissue homeostasis. The accumulation of damaged proteins contributes to multiple age- related diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease. Damaged proteins are degraded by the ubiquitin–proteasome system or through autophagy-lysosome, key components of the proteostasis network. Modulation of either proteasome activity or autophagic-lysosomal potential extends lifespan and protects organisms from symptoms associated with proteostasis disorders, suggesting that protein clearance mechanisms are directly linked to ageing and age-associated diseases. he integrity of the proteome, or proteostasis, is challenged during the ageing process. Damaged proteins accumulate as a consequence of ageing and may ensue from the Taccumulation of reactive oxygen species and a progressive decline in the ability to maintain a functional proteome1. This demise in proteostasis is considered one of the hallmarks of ageing1 and contributes to multiple age-related diseases such as Alzheimer’s (AD)2, Parkinson’s (PD)3 or Huntington’s disease (HD)4. Proteostasis is maintained by a network of cellular mechanisms that monitors folding, concentration, cellular localization and interactions of proteins from their synthesis through their degradation5. Chaperones assure the proper folding of proteins throughout their life cycle and under stress conditions but their activity declines with age (reviewed in refs 6–10).
    [Show full text]
  • Produktinformation
    Produktinformation Diagnostik & molekulare Diagnostik Laborgeräte & Service Zellkultur & Verbrauchsmaterial Forschungsprodukte & Biochemikalien Weitere Information auf den folgenden Seiten! See the following pages for more information! Lieferung & Zahlungsart Lieferung: frei Haus Bestellung auf Rechnung SZABO-SCANDIC Lieferung: € 10,- HandelsgmbH & Co KG Erstbestellung Vorauskassa Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 Zuschläge F. +43(0)1 489 3961-7 [email protected] • Mindermengenzuschlag www.szabo-scandic.com • Trockeneiszuschlag • Gefahrgutzuschlag linkedin.com/company/szaboscandic • Expressversand facebook.com/szaboscandic PSMD10 Antibody, Biotin conjugated Product Code CSB-PA018899LD01HU Abbreviation 26S proteasome non-ATPase regulatory subunit 10 Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Uniprot No. O75832 Immunogen Recombinant Human 26S proteasome non-ATPase regulatory subunit 10 protein (1-226AA) Raised In Rabbit Species Reactivity Human Tested Applications ELISA Relevance Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC). In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. Independently of the proteasome, regulates EGF-induced AKT activation through inhibition of the RHOA/ROCK/PTEN pahway, leading to prolonged AKT activation. Plays an important role in RAS-induced tumorigenesis. Acts as an proto-oncoprotein by being involved in negative regulation of tumor suppressors RB1 and p53/TP53. Overexpression is leading to phosphorylation of RB1 and proteasomal degradation of RB1. Regulates CDK4-mediated phosphorylation of RB1 by competing with CDKN2A for binding with CDK4. Facilitates binding of MDM2 to p53/TP53 and the mono- and polyubiquitination of p53/TP53 by MDM2 suggesting a function in targeting the TP53:MDM2 complex to the 26S proteasome.
    [Show full text]
  • PSMD10 Antibody (Center) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AW5126
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PSMD10 Antibody (Center) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AW5126 Specification PSMD10 Antibody (Center) - Product Information Application IF, WB, IHC-P,E Primary Accession O75832 Other Accession Q9Z2X2 Reactivity Human Predicted Mouse Host Rabbit Clonality Polyclonal Calculated MW H=24,16;M=25;Ra t=25 KDa Isotype Rabbit Ig Antigen Source HUMAN PSMD10 Antibody (Center) - Additional Information Gene ID 5716 Fluorescent image of Hela cells stained with PSMD10 Antibody (Center)(Cat#AW5126). Antigen Region AW5126 was diluted at 1:25 dilution. An 43-76 Alexa Fluor 488-conjugated goat anti-rabbit lgG at 1:400 dilution was used as the Other Names secondary antibody (green). Cytoplasmic 26S proteasome non-ATPase regulatory subunit 10, 26S proteasome regulatory actin was counterstained with Alexa Fluor® subunit p28, Gankyrin, p28(GANK), PSMD10 555 conjugated with Phalloidin (red). Dilution IF~~1:25 WB~~ 1:1000 IHC-P~~1:25 Target/Specificity This PSMD10 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 43-76 amino acids from the Central region of human PSMD10. Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. Western blot analysis of lysates from MCF-7, PC-3, K562 cell line (from left to right), using Storage PSMD10 Antibody (Center)(Cat. #AW5126). Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Maintain refrigerated at 2-8°C for up to 2 AW5126 was diluted at 1:1000 at each lane.
    [Show full text]
  • A High Resolution Physical and RH Map of Pig Chromosome 6Q1.2 And
    A high resolution physical and RH map of pig chromosome 6q1.2 and comparative analysis with human chromosome 19q13.1 Flávia Martins-Wess, Denis Milan, Cord Drögemüller, Rodja Voβ-Nemitz, Bertram Brenig, Annie Robic, Martine Yerle, Tosso Leeb To cite this version: Flávia Martins-Wess, Denis Milan, Cord Drögemüller, Rodja Voβ-Nemitz, Bertram Brenig, et al.. A high resolution physical and RH map of pig chromosome 6q1.2 and comparative analysis with human chromosome 19q13.1. BMC Genomics, BioMed Central, 2003, 4, pp.435-444. 10.1186/1471-2164-4- 20. hal-02680244 HAL Id: hal-02680244 https://hal.inrae.fr/hal-02680244 Submitted on 31 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. BMC Genomics BioMed Central Research article Open Access A high resolution physical and RH map of pig chromosome 6q1.2 and comparative analysis with human chromosome 19q13.1 Flávia Martins-Wess1, Denis Milan*2, Cord Drögemüller1, Rodja Voβ- Nemitz1, Bertram Brenig3, Annie Robic2, Martine Yerle2 and Tosso Leeb*1 Address: 1Institute of Animal Breeding and Genetics, School of Veterinary Medicine Hannover, Bünteweg 17p, 30559 Hannover, Germany, 2Institut National de la Recherche Agronomique (INRA), Laboratoire de Génétique Cellulaire, BP27, 31326 Castanet Tolosan Cedex, France and 3Institute of Veterinary Medicine, University of Göttingen, Groner Landstr.
    [Show full text]
  • Functional Gene Clusters in Global Pathogenesis of Clear Cell Carcinoma of the Ovary Discovered by Integrated Analysis of Transcriptomes
    International Journal of Environmental Research and Public Health Article Functional Gene Clusters in Global Pathogenesis of Clear Cell Carcinoma of the Ovary Discovered by Integrated Analysis of Transcriptomes Yueh-Han Hsu 1,2, Peng-Hui Wang 1,2,3,4,5 and Chia-Ming Chang 1,2,* 1 Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan; [email protected] (Y.-H.H.); [email protected] (P.-H.W.) 2 School of Medicine, National Yang-Ming University, Taipei 112, Taiwan 3 Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan 4 Department of Medical Research, China Medical University Hospital, Taichung 440, Taiwan 5 Female Cancer Foundation, Taipei 104, Taiwan * Correspondence: [email protected]; Tel.: +886-2-2875-7826; Fax: +886-2-5570-2788 Received: 27 April 2020; Accepted: 31 May 2020; Published: 2 June 2020 Abstract: Clear cell carcinoma of the ovary (ovarian clear cell carcinoma (OCCC)) is one epithelial ovarian carcinoma that is known to have a poor prognosis and a tendency for being refractory to treatment due to unclear pathogenesis. Published investigations of OCCC have mainly focused only on individual genes and lack of systematic integrated research to analyze the pathogenesis of OCCC in a genome-wide perspective. Thus, we conducted an integrated analysis using transcriptome datasets from a public domain database to determine genes that may be implicated in the pathogenesis involved in OCCC carcinogenesis. We used the data obtained from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) DataSets. We found six interactive functional gene clusters in the pathogenesis network of OCCC, including ribosomal protein, eukaryotic translation initiation factors, lactate, prostaglandin, proteasome, and insulin-like growth factor.
    [Show full text]
  • UVB-Mediated Down-Regulation of Proteasome in Cultured Human Primary Pterygium Fibroblasts Alexios J
    Aletras et al. BMC Ophthalmology (2018) 18:328 https://doi.org/10.1186/s12886-018-0987-8 RESEARCH ARTICLE Open Access UVB-mediated down-regulation of proteasome in cultured human primary pterygium fibroblasts Alexios J. Aletras1* , Ioannis Trilivas2, Maria-Elpida Christopoulou1, Sotiria Drakouli1,3, Constantine D. Georgakopoulos2 and Nikolaos Pharmakakis2 Abstract Background: Pterygium is a condition characterized by epithelial overgrowth of the cornea, inflammatory cell infiltration and an abnormal extracellular matrix accumulation. Chronic UV exposure is considered as a pathogenic factor of this disease. Proteasome is an intracellular multi-subunit protease complex that degrades intracellular proteins. Among proteasome subunits the β5 (PSMB5), bearing chymotrypsin-like activity. It is considered as the main proteasome subunit and its expression is mediated by Nrf2-ARE pathway in many cell types. This study investigates the expression of PSMB5 in pterygium and the effect of UVB irradiation on its expression and activity in pterygium fibroblasts. Methods: Normal conjunctival and pterygium specimens were obtained from the bulbar conjunctiva of patients undergoing cataract surgery and from patients with pterygium undergoing surgical removal of primary tissue, respectively. Fibroblasts were isolated upon treatment of specimens with clostridium collagenase. The expression of PSMB5 and Nrf2 in tissues and cells was ascertained by RT-PCR analysis and western blotting. Cell survival was measured by the MTT method and the proteasome chymotrypsin-like activity was determined by fluorometry. Results: RT-PCR analysis showed that the expression of PSMB5 was significantly lower in pterygium than in normal conjunctiva. The expression of PSMB5 was mediated by the Nrf2/ARE pathway as indicated by using the Nrf2 activator Oltipraz.
    [Show full text]
  • A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection
    CLINICAL RESEARCH www.jasn.org A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection Weijia Zhang,1 Zhengzi Yi,1 Karen L. Keung,2 Huimin Shang,3 Chengguo Wei,1 Paolo Cravedi,1 Zeguo Sun,1 Caixia Xi,1 Christopher Woytovich,1 Samira Farouk,1 Weiqing Huang,1 Khadija Banu,1 Lorenzo Gallon,4 Ciara N. Magee,5 Nader Najafian,5 Milagros Samaniego,6 Arjang Djamali ,7 Stephen I. Alexander,2 Ivy A. Rosales,8 Rex Neal Smith,8 Jenny Xiang,3 Evelyne Lerut,9 Dirk Kuypers,10,11 Maarten Naesens ,10,11 Philip J. O’Connell,2 Robert Colvin,8 Madhav C. Menon,1 and Barbara Murphy1 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background In kidney transplant recipients, surveillance biopsies can reveal, despite stable graft function, histologic features of acute rejection and borderline changes that are associated with undesirable graft outcomes. Noninvasive biomarkers of subclinical acute rejection are needed to avoid the risks and costs associated with repeated biopsies. Methods We examined subclinical histologic and functional changes in kidney transplant recipients from the prospective Genomics of Chronic Allograft Rejection (GoCAR) study who underwent surveillance biopsies over 2 years, identifying those with subclinical or borderline acute cellular rejection (ACR) at 3 months (ACR-3) post-transplant. We performed RNA sequencing on whole blood collected from 88 indi- viduals at the time of 3-month surveillance biopsy to identify transcripts associated with ACR-3, developed a novel sequencing-based targeted expression assay, and validated this gene signature in an independent cohort.
    [Show full text]
  • Drives Nuclear FOXO Proteolysis
    OPEN Oncogene (2018) 37, 363–376 www.nature.com/onc ORIGINAL ARTICLE Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis F Zhang1, DM Virshup1,2,3 and JK Cheong1 Evasion of forkhead box O (FOXO) family of longevity-related transcription factors-mediated growth suppression is necessary to promote cancer development. Since somatic alterations or mutations and transcriptional dysregulation of the FOXO genes are infrequent in human cancers, it remains unclear how these tumour suppressors are eliminated from cancer cells. The protein stability of FOXO3A is regulated by Casein Kinase 1 alpha (CK1α) in an oncogenic RAS-specific manner, but whether this mode of regulation extends to related FOXO family members is unknown. Here we report that CK1α similarly destabilizes FOXO4 in RAS- mutant cells by phosphorylation at serines 265/268. The CK1α-dependent phosphoregulation of FOXO4 is primed, in part, by the PI3K/AKT effector axis of oncogenic RAS signalling. In addition, mutant RAS coordinately elevates proteasome subunit expression and proteolytic activity to eradicate nuclear FOXO4 proteins from RAS-mutant cancer cells. Importantly, dual inhibition of CK1α and the proteasome synergistically inhibited the growth of multiple RAS-mutant human cancer cell lines of diverse tissue origin by blockade of nuclear FOXO4 degradation and induction of caspase-dependent apoptosis. Our findings challenge the current paradigm that nuclear export regulates the proteolysis of FOXO3A/4 tumour suppressors in the context of cancer and illustrates how oncogenic
    [Show full text]
  • Deubiquitinase UCHL1 Maintains Protein Homeostasis Through the PSMA7-APEH- Proteasome Axis in High-Grade Serous Ovarian Carcinoma
    Author Manuscript Published OnlineFirst on March 22, 2021; DOI: 10.1158/1541-7786.MCR-20-0883 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH- Proteasome Axis in High-Grade Serous Ovarian Carcinoma Apoorva Tangri1*, Kinzie Lighty1*, Jagadish Loganathan1, Fahmi Mesmar2, Ram Podicheti3, Chi Zhang4, Marcin Iwanicki5, Ronny Drapkin6, Harikrishna Nakshatri7,8, Sumegha Mitra1,8,# 1Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA 2Department of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA 3Center for Genomics and Bioinformatics, Indiana University, Bloomington, IN, USA 4Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA 5Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, USA 6Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 7Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 8Indiana University Simon Comprehensive Cancer Center, Indianapolis, USA *Equal contribution Running title: UCHL1 mediates protein homeostasis in HGSOC Conflict of interest disclosure statement: None #Corresponding author Sumegha Mitra, Ph.D. Assistant Professor of Obstetrics and Gynecology Indiana University School of Medicine C547 Joseph E. Walther Hall (R3) 980 W Walnut Street, Indianapolis, IN 46202 317-274-3967 (office) 317-944-7417 (fax) [email protected] 1 Downloaded from mcr.aacrjournals.org on October 1, 2021. © 2021 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 22, 2021; DOI: 10.1158/1541-7786.MCR-20-0883 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma
    Published OnlineFirst January 4, 2019; DOI: 10.1158/1078-0432.CCR-18-2363 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma Hongxia Xu1,2, Huiying Han1, Sha Song1, Nengjun Yi3, Chen'ao Qian4, Yingchun Qiu1, Wenqi Zhou1, Yating Hong5, Wenyue Zhuang6, Zhengyi Li7, Bingzong Li5, and Wenzhuo Zhuang1 Abstract Purpose: How exosomal RNAs released within the bone Results: We identified that PSMA3 and PSMA3-AS1 in MSCs marrow microenvironment affect proteasome inhibitors' (PI) could be packaged into exosomes and transferred to myeloma sensitivity of multiple myeloma is currently unknown. This cells, thus promoting PI resistance. PSMA3-AS1 could form an study aims to evaluate which exosomal RNAs are involved and RNA duplex with pre-PSMA3, which transcriptionally promot- by which molecular mechanisms they exert this function. ed PSMA3 expression by increasing its stability. In xenograft Experimental Design: Exosomes were characterized by models, intravenously administered siPSMA3-AS1 was found dynamic light scattering, transmission electron microscopy, and to be effective in increasing carfilzomib sensitivity. Moreover, Western blot analysis. Coculture experiments were performed to plasma circulating exosomal PSMA3 and PSMA3-AS1 derived assess exosomal RNAs transferring from mesenchymal stem from patients with multiple myeloma were significantly asso- cells (MSC) to multiple myeloma cells. The role of PSMA3-AS1 ciated with PFS and OS. in PI sensitivity was further evaluated in vivo. To determine the Conclusions: This study suggested a unique role of exoso- prognostic significance of circulating exosomal PSMA3 and mal PSMA3 and PSMA3-AS1 in transmitting PI resistance from PSMA3-AS1, a cohort of patients with newly diagnosed multiple MSCs to multiple myeloma cells, through a novel exosomal myeloma was enrolled to study.
    [Show full text]